[Preliminary study of DA or HA regimen chemotherapy for the treatment of refractory and relapsed paroxysmal nocturnal hemoglobinuria].

Abstract

OBJECTIVE:

To observe the efficacy and side effect of DA/HA regimen chemotherapy for the treatment of refractory and relapsed paroxysmal nocturnal hemoglobinuria (PNH).

METHODS:

Eight patients with refractory and relapsed PNH were treated with DA/HA regimen chemotherapy. Three patients were treated with DA (DNR 40 mg/d, i.v.drip, the first and the second day; 20 mg/d, i.v.drip, the third day; Ara-C 100 mg/d, i.v.drip, for 5 days) and 5 patients with HA (HHT 2 - 3 mg/d, i.v.drip, for 5 days; Ara-C 100 mg/d, i.v.drip, for 5 days).

RESULTS:

All the 8 patients responded well: the PNH clone was diminished in five patients. Hemolysis was remitted in 6 cases. Five patients showed improvement in hematological parameters. The dosage of corticosteroid was decreased in all of them. No serious side effect was revealed.

CONCLUSION:

DA/HA regimen chemotherapy was safe and effective for refractory and relapsed PNH patients.

• Authors: Yan-ran Cao, Zong-hong Shao, Hai-rong Jia, Juan Sun, Hong Liu, Yu-hong Wu, Tie-jun Qin, Jun Shi, Jie Bai, Guang-sheng He, Rong Fu, Ming-feng Zhao, Hai-feng Tu, Zhen-zhu Cui, Tian-ying Yang
• Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (Zhonghua Xue Ye Xue Za Zhi) Vol. 25 Issue 4 Pg. 202-4 (Apr 2004) ISSN: 0253-2727 [Print] China
• PMID: 15182555 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Glycosylphosphatidylinositols
• Harringtonines
• Cytarabine
• harringtonin
• Daunorubicin

Topics

• Adolescent
• Adult
• Cytarabine (administration & dosage)
• Daunorubicin (administration & dosage)
• Drug Therapy, Combination
• Female
• Glycosylphosphatidylinositols (analysis)
• Harringtonines
• Hemoglobinuria, Paroxysmal (drug therapy)
• Humans
• Male